Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease.

ABSTRACT:

Introduction

We evaluated the selective M1 muscarinic positive allosteric modulator, MK-7622, as adjunctive cognitive enhancing therapy in individuals with Alzheimer's disease.

Methods

A randomized, double-blind, proof-of-concept trial was performed. Participants with mild-to-moderate Alzheimer's disease, being treated with an acetylcholinesterase inhibitor, were randomized 1:1 to 45 mg of MK-7622 or placebo for 24 weeks. Endpoints included the mean change from baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog₁₁) at 12 weeks and Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory at 24 weeks.

Results

Two hundred forty participants were randomized. The trial was stopped for futility after meeting prospective

SUBMITTER: Voss T 

PROVIDER: S-EPMC6021552 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature